Price Chart

Profile

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
URL https://www.cytosorbents.com
Investor Relations URL https://cytosorbents.com/investor-relations/overview
HQ State/Province New Jersey
Sector Health Care
Industry Health Care Equipment & Supplies
Equity Style Small Cap/Value
Next Earnings Release Mar. 14, 2025 (est.)
Last Earnings Release Nov. 07, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
URL https://www.cytosorbents.com
Investor Relations URL https://cytosorbents.com/investor-relations/overview
HQ State/Province New Jersey
Sector Health Care
Industry Health Care Equipment & Supplies
Equity Style Small Cap/Value
Next Earnings Release Mar. 14, 2025 (est.)
Last Earnings Release Nov. 07, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A